How was published evidence used in model-based cost-utility analysis for lung cancer?
Abstract Background Model-based cost-utility analysis (CUA) is a widely used method for evaluating the value of innovative medicines for lung cancer. However, comprehensive evidence exploring the sources of input parameters for CUA modeling is lacking. The objective of this study was to analyze the...
Saved in:
| Main Authors: | Haijing Guan, Chunping Wang, Ruowei Xiao, Ting Zhou, Wei Li, Yanan Xu, Hongting Nie, Zhigang Zhao, Sheng Han, Feng Xie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Health Economics Review |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13561-025-00651-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single-chamber pacemakers: with or without leads? Cost-effectiveness and cost-utility analyses
by: José Ramón Lago-Quinteiro, et al.
Published: (2025-12-01) -
Cost utility analysis of antibiotics compared with operative treatment in uncomplicated acute appendicitis
by: Napaphat Poprom, et al.
Published: (2025-04-01) -
Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis
by: Ryan J. Bamforth, et al.
Published: (2024-11-01) -
METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES
by: R. I. Yagudina, et al.
Published: (2015-03-01) -
Enhancing healthcare cost transparency: assessing implementation challenges, criticisms, and alternative solutions
by: Sonia Ali Malik
Published: (2025-01-01)